ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

BAFF Inhibition to Prevent Antibody Rebound Following Proteasome Inhibitor-Based Desensitization: A Randomized, Controlled Trial

S. Tremblay1, A. Rike-Shields2, A. Govil1, M. Cardi3, P. Brailey1, R. Alloway1, E. Woodle1

1U Cincinnati, Cincinnati, OH, 2Surgery, U Cincinnati, Christ Hospital, Cincinnati, OH, 3Christ Hospital, Cincinnati, OH

Meeting: 2020 American Transplant Congress

Abstract number: 568

Keywords: Antibodies, B cells, Bone marrow, Kidney

Session Information

Date: Saturday, May 30, 2020

Session Name: Kidney Immunosuppression: Desensitization

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:15pm-3:27pm

Location: Virtual

Related Abstracts
  • A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.
  • Prospective, Iterative, Phased, Trial of Proteasome Inhibitor-Based Desensitization in Highly Sensitized Renal Transplant Candidates, A

*Purpose: Proteasome inhibitor (PI) therapy reduces bone marrow plasma cells and HLA antibodies (Abs) in renal transplant candidates. However, rebound is common in many patients (pts). Increases in BAFF levels occur after B cell depletion, and may be an important mechanism Ab rebound, which may be reduced by belimumab, a BAFF inhibitor. Results from a RCT of bortezomib desensitization, with or without belimumab, are presented.

*Methods: All pts received 2 cycles of bortezomib (1.3mg/m2) with plasmapheresis before the 1st and 4th dose of each cycle. In group A, no additional treatment was administered. In group B, pts received belimumab 10mg/kg IV on days 0, 10, 28, 37, 65, 94, and 121. Primary endpoints were safety and reduction in immunodominant Ab (iAb), measeured by single antigen beads. cPRA was calculated using a precision PRA calculator and donors required to match (DRTM) were defined as (1/1-cPRA) and fold decrease in DRTM as (DRTM pre-DS/DRTM post-DS).

*Results: 10 pts were enrolled and are included in the safety analysis. 2 pts in group A and 4 in group B reached the primary endpoint (others: transplanted [3], adverse event [1], died [1]) and are included in efficacy analysis. Mean age was 46, 70% were Caucasian and female, and median cPRA was 99.41%. Treatment was well tolerated; 2 pts had a grade >3 toxicity. 2 patients reported paresthesia. 5/6 pts had class II iAbs, and 4/6 pts required dilutional analyses due to SAB saturation. All pts had an iAb reduction by day 39 (mean 62.4% and 57.0% for groups A and B respectively), which persisted in 50% in group A and 75% in group B by day 151 (range 3.6% to 62.1%, see Table 1). Figure 1A details individual change in iAb, Figure 1B fold decrease in #DRTM, and 1C change in the number of HLA Abs.

*Conclusions: Belimumab therapy was well tolerated, with all pts having a reduction in iAb and #DRTM. 2/4 pts receiving belimumab had substantial long-term suppression of iAb levels, supporting continued evaluation of belimumab.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Tremblay S, Rike-Shields A, Govil A, Cardi M, Brailey P, Alloway R, Woodle E. BAFF Inhibition to Prevent Antibody Rebound Following Proteasome Inhibitor-Based Desensitization: A Randomized, Controlled Trial [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/baff-inhibition-to-prevent-antibody-rebound-following-proteasome-inhibitor-based-desensitization-a-randomized-controlled-trial/. Accessed February 25, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Left-Sided Donor Nephrectomy Predisposes Living Kidney Donors to Latent Adrenal Insufficiency with Symptoms of Fatigue and Inferior Quality of Life.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.